Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

The present state of antineoplaston research (1).

Burzynski SR.

Integr Cancer Ther. 2004 Mar;3(1):47-58. Review.

PMID:
15035876
2.

Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.

Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2004;5(6):315-26.

PMID:
15563234
3.

Recent review of research on a technique for treating cancer.

Vickers A.

Integr Cancer Ther. 2004 Sep;3(3):199; author reply 200. No abstract available.

PMID:
15312259
4.
6.
7.

Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case.

Ogata Y, Tsuda H, Matono K, Kumabe T, Saitsu H, Hara H, Akagi Y, Araki Y, Sata M, Shirouzu K.

Surg Today. 2003;33(6):448-53.

PMID:
12768372
8.

Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.

Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2003;4(2):91-101.

PMID:
12718563
9.

Commentary: The response and survival of children with recurrent diffuse intrisic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma, by Burzynski G, et al.

Massimino M, Clerici CA.

Childs Nerv Syst. 2014 Dec;30(12):2065-6. doi: 10.1007/s00381-014-2511-7. Epub 2014 Jul 31. No abstract available.

PMID:
25079885
10.

Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.

Burzynski SR, Janicki TJ, Weaver RA, Burzynski B.

Integr Cancer Ther. 2006 Mar;5(1):40-7.

PMID:
16484713
11.

The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.

Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A.

Childs Nerv Syst. 2014 Dec;30(12):2051-61. doi: 10.1007/s00381-014-2401-z. Epub 2014 Apr 10.

13.

A novel strategy for remission induction and maintenance in cancer therapy.

Tsuda H, Sata M, Ijuuin H, Kumabe T, Uchida M, Ogou Y, Akagi Y, Shirouzu K, Hara H, Nakashima Y.

Oncol Rep. 2002 Jan-Feb;9(1):65-8.

PMID:
11748457
14.

Complete response and long-term survival (>20 years) of a child with tectal glioma: a case report.

Burzynski SR, Burzynski GS, Janicki TJ, Marszalek A.

Pediatr Neurosurg. 2015;50(2):99-103. doi: 10.1159/000369907. Epub 2015 Apr 22.

16.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
17.

Molecular cloning and characterization of a novel human BTB domain-containing gene, BTBD10, which is down-regulated in glioma.

Chen J, Xu J, Ying K, Cao G, Hu G, Wang L, Luo C, Lou M, Mao Y, Xie Y, Lu Y.

Gene. 2004 Sep 29;340(1):61-9.

PMID:
15556295
18.

The effect of Antineoplaston, a new antitumor agent on malignant brain tumors.

Sugita Y, Tsuda H, Maruiwa H, Hirohata M, Shigemori M, Hara H.

Kurume Med J. 1995;42(3):133-40.

19.

Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.

Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H.

Kurume Med J. 1996;43(2):137-47.

20.

Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.

Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WP, Lim S, Figg WD.

Mayo Clin Proc. 1999 Feb;74(2):137-45.

PMID:
10069350

Supplemental Content

Support Center